Alluvi, previously BI 4744, offers a promising breakthrough in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling effectiveness in clinical studies, potentially outperforming available G